<DOC>
	<DOCNO>NCT02764554</DOCNO>
	<brief_summary>The purpose post-marketing surveillance ( PMS ) observe safety profile Lenvima ( lenvatinib ) normal clinical practice setting .</brief_summary>
	<brief_title>Post-Marketing Surveillance Lenvima Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : Participants meet follow criterion eligible inclusion study : 1 . Participants approve indication lenvatinib Korea 2 . Participants write consent use personal medical information study purpose Investigators refer approve indication contraindication regard exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Post-Marketing Surveillance</keyword>
	<keyword>Lenvima</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>E7080</keyword>
	<keyword>Differentiated thyroid carcinoma</keyword>
	<keyword>Refractory radioactive iodine</keyword>
	<keyword>Progressive</keyword>
	<keyword>locally recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>